Pleural mesothelioma (WP5087)
Homo sapiens
Mesothelioma
Authors
Franziska Kreidl , Marvin Martens , Eric Weitz , Finterly Hu , Egon Willighagen , Lauren J. Dupuis , Alex Pico , Lars Willighagen , and Kristina HanspersActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
- A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma (2022).
- Autistic spectrum disorder (ASD) - Gene, molecular and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopmen (2023).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
CPTAC Rare DiseasesAnnotations
Disease Ontology
malignant pleural mesotheliomaPathway Ontology
disease pathway altered autophagy pathwayCell Type Ontology
mesothelial cell of pleura mesothelial cellReferences
- Biomolecular Pathways and Malignant Pleural Mesothelioma. Jaurand MC, Jean D. In: Malignant Pleural Mesothelioma: Present Status and Future Directions [Internet]. BENTHAM SCIENCE PUBLISHERS; 2016. p. 169–92. Available from: http://dx.doi.org/10.2174/9781681081946116010017 DOI Scholia
- Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Klominek J, Sumitran Karuppan S, Hauzenberger D. Int J Cancer. 1997 Sep 17;72(6):1034–44. PubMed Europe PMC Scholia
- The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. Cancer. 2003 Feb 25;99(1):51–6. PubMed Europe PMC Scholia
- Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Liu Z, Klominek J. Thorax. 2003 Mar;58(3):198–203. PubMed Europe PMC Scholia
- Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Edwards JG, McLaren J, Jones JL, Waller DA, O’Byrne KJ. Br J Cancer. 2003 May 19;88(10):1553–9. PubMed Europe PMC Scholia
- Wnt signaling in disease and in development. Nusse R. Cell Res. 2005 Jan;15(1):28–32. PubMed Europe PMC Scholia
- Molecular pathways in malignant pleural mesothelioma. Whitson BA, Kratzke RA. Cancer Lett. 2006 Aug 8;239(2):183–9. PubMed Europe PMC Scholia
- Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, et al. PLoS One. 2009 Sep 15;4(9):e7016. PubMed Europe PMC Scholia
- An emerging model for BAP1’s role in regulating cell cycle progression. Eletr ZM, Wilkinson KD. Cell Biochem Biophys. 2011 Jun;60(1–2):3–11. PubMed Europe PMC Scholia
- New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. Am J Pathol. 2013 Apr;182(4):1065–77. PubMed Europe PMC Scholia
- BAP1 and cancer. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. Nat Rev Cancer. 2013 Mar;13(3):153–9. PubMed Europe PMC Scholia
- Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Sallé F, Cazes A, et al. Oncogene. 2014 Jul 10;33(28):3748–52. PubMed Europe PMC Scholia
- RASSF tumor suppressor gene family: biological functions and regulation. Volodko N, Gordon M, Salla M, Ghazaleh HA, Baksh S. FEBS Lett. 2014 Aug 19;588(16):2671–84. PubMed Europe PMC Scholia
- The ins and outs of fibroblast growth factor receptor signalling. Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP. Clin Sci (Lond). 2014 Aug;127(4):217–31. PubMed Europe PMC Scholia
- Reactive oxygen species a double-edged sword for mesothelioma. Benedetti S, Nuvoli B, Catalani S, Galati R. Oncotarget. 2015 Jul 10;6(19):16848–65. PubMed Europe PMC Scholia
- Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Urso L, Calabrese F, Favaretto A, Conte P, Pasello G. Crit Rev Oncol Hematol. 2016 Jan;97:220–30. PubMed Europe PMC Scholia
- The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. J Thorac Oncol. 2016 Oct;11(10):1615–26. PubMed Europe PMC Scholia
- YAP/TAZ at the Roots of Cancer. Zanconato F, Cordenonsi M, Piccolo S. Cancer Cell. 2016 Jun 13;29(6):783–803. PubMed Europe PMC Scholia
- Genomic Landscape of Malignant Mesotheliomas. Kato S, Tomson BN, Buys TPH, Elkin SK, Carter JL, Kurzrock R. Mol Cancer Ther. 2016 Oct;15(10):2498–507. PubMed Europe PMC Scholia
- Rassf Proteins as Modulators of Mst1 Kinase Activity. Bitra A, Sistla S, Mariam J, Malvi H, Anand R. Sci Rep. 2017 Mar 22;7:45020. PubMed Europe PMC Scholia
- BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. Nature. 2017 Jun 22;546(7659):549–53. PubMed Europe PMC Scholia
- Novel insights into mesothelioma biology and implications for therapy. Yap TA, Aerts JG, Popat S, Fennell DA. Nat Rev Cancer. 2017 Jul 25;17(8):475–88. PubMed Europe PMC Scholia
- Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Hylebos M, Van Camp G, Vandeweyer G, Fransen E, Beyens M, Cornelissen R, et al. Oncotarget. 2017 Dec 1;8(69):113673–86. PubMed Europe PMC Scholia
- Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Sekido Y. Cancers (Basel). 2018 Mar 22;10(4):90. PubMed Europe PMC Scholia
- The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. Liu XL, Zuo R, Ou WB. J Cancer Res Clin Oncol. 2018 Nov;144(11):2097–106. PubMed Europe PMC Scholia
- Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Dobrokhotov O, Samsonov M, Sokabe M, Hirata H. Clin Transl Med. 2018 Aug 13;7(1):23. PubMed Europe PMC Scholia
- Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Chapel DB, Churg A, Santoni-Rugiu E, Tsujimura T, Hiroshima K, Husain AN. Lung Cancer. 2019 Jan;127:69–75. PubMed Europe PMC Scholia
- Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. CA Cancer J Clin. 2019 Sep;69(5):402–29. PubMed Europe PMC Scholia
- Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Yuan X, Larsson C, Xu D. Oncogene. 2019 Aug;38(34):6172–83. PubMed Europe PMC Scholia
- The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Chu GJ, van Zandwijk N, Rasko JEJ. Front Oncol. 2019 Dec 6;9:1366. PubMed Europe PMC Scholia
- Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Clin Cancer Res. 2020 Jul 15;26(14):3819–30. PubMed Europe PMC Scholia
- TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends. Yuan X, Dai M, Xu D. Cancer Lett. 2020 Nov 28;493:1–9. PubMed Europe PMC Scholia
- Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Cakiroglu E, Senturk S. Int J Mol Sci. 2020 Sep 1;21(17):6342. PubMed Europe PMC Scholia
- Fundamental insights into the interaction between telomerase/TERT and intracellular signaling pathways. Ghareghomi S, Ahmadian S, Zarghami N, Kahroba H. Biochimie. 2021 Feb;181:12–24. PubMed Europe PMC Scholia
- TERT-Regulation and Roles in Cancer Formation. Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. Front Immunol. 2020 Nov 19;11:589929. PubMed Europe PMC Scholia
- Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Masclef L, Ahmed O, Estavoyer B, Larrivée B, Labrecque N, Nijnik A, et al. Cell Death Differ. 2021 Feb;28(2):606–25. PubMed Europe PMC Scholia
- Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. Morani F, Bisceglia L, Rosini G, Mutti L, Melaiu O, Landi S, et al. Int J Mol Sci. 2021 Mar 8;22(5):2738. PubMed Europe PMC Scholia
- Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Napoli F, Listì A, Zambelli V, Witel G, Bironzo P, Papotti M, et al. Cancers (Basel). 2021 May 24;13(11):2564. PubMed Europe PMC Scholia
- Biological basis for novel mesothelioma therapies. Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, et al. Br J Cancer. 2021 Oct;125(8):1039–55. PubMed Europe PMC Scholia